릴게임백경 24.rcu914.top 바로가기 바다이야기 꽁 머니 환전, 올쌈바

바다이야기 무료게임 다운로드 84.rcu914.top 릴게임오션파라다이스

바다신2영상 94.rcu914.top 사설바둑이

무료온라인게임 84.rcu914.top 백경게임다운로드

중고게임기 매매 53.rcu914.top 야마토게임하기

야마토게임장주소 57.rcu914.top Pg 소프트 무료 체험

무료바다이야기게임 50.rcu914.top 바다이야기 예시

바다이야기예시 12.rcu914.top 모바일신천지모바일

하이로우하는법 82.rcu914.top 오션파라다이스다운

온라인 슬롯 배팅법 44.rcu914.top 강시

바둑이넷마블 55.rcu914.top 체리마스터 다운

바로가기 go !! 바로가기 go !!

한게임바둑이 매장판 바다이야기 빠칭코 슬롯머신 야마토게임 하기 고전릴게임 용의눈게임 프라그마틱 슬롯 슬롯머신추천 릴게임뜻 황금성3게임공략법 파칭코 야마토3게임 다운로드 하기 릴황 금성 오션파라다이스 카카오 야마토 먹튀 유희왕황금성 황금성배당줄 게임몰 야마토게임 하기 바다이야기릴게임 프라그마틱 무료체험 손오공바다이야기 야마토릴게임 황금포커성 야마토 릴게임 손오공 온라인 게임 무료충전 릴 게임 강원랜드 슬롯머신 종류 황금성온라인게임 인터넷야마토주소 무료 슬롯 머신 다운 받기 오리지널야마토 프라그마틱 순위 릴게임 먹튀보증 신야마토 황금성게임장 한게임머니파는곳 황금성배당 슬롯무료체험 황금성갈갈이 슬롯 게시판 일본 야마토 게임 황금성갈갈이 우주전함 야마토 2202 야마토2 릴게임 파칭코 어플 신천지 게임 공략법 오션파라다이스하는방법 체리마스터 비법 황금성동영상 바다이야기슬롯 파칭코슬롯 릴게임골드몽사이트 바다이야기 환전 가능 바다이야기 pc버전 골드몽게임 온라인빠찡고 최신릴게임 릴게임 신천지사이트 릴온라인 신천지 슬롯추천 신천지 무료게임 릴게임 무료충전게임 바다이야기사이트 양귀비게임설명 오션릴게임 온라인슬롯사이트 황금포커성 백경게임다운로드 프라그마틱 슬롯 무료 골드몽 먹튀 신천지 게임 공략법 로드할 오리지날야마토연타예시 슬롯 머신 이기는 방법 황금성게임 인터넷릴게임 다빈치무료릴게임 황금성 게임랜드 황금성다운 릴게임 추천 사이트 황금성 슬롯 슬롯머신 무료 잭팟 모바일파칭코 황금성오리지널 슬롯머신 판매 중고 손오공예시 황금포카성 카카오야마토 슬롯 무료체험 릴게임동영상 릴게임 먹튀보증 바다이야기 프로그램 릴게임 다빈치 온라인릴게임 먹튀 검증 백경게임 빠칭코게임 손오공 온라인 게임 황금성pc버전 창공릴게임 야마토카지노 프라그마틱 무료게임 오션파라다이스하는방법 바다이야기상어 종합 릴게임 릴게임 사이트 야마토2 pc버전 인터넷빠찡꼬 스위피릴게임 황금성게임어플 바다이야기 꽁 머니 환전 신천지게임다운로드 최신게임 바다이야기 하는 법 야마토2 릴게임 온라인 릴게임 정보 야마토 2 다운로드 한게임머니파는곳 릴게임뽀빠이 야마토무료게임 바다이야기시즌5 릴게임 종류 This article was released as Pharm Edaily Premium Content on October 21, 2025, at 8:17 AM.


[NA Eun-kyung, Edaily Reporter] As the KOSPI closed above 3,800 for the first time and the KOSDAQ also gained on the October 20th, stem cell therapy-related stocks led the rally in South Korea’s pharmaceutical and healthcare sector. T&R BIOFAB, which had been falling since an나노엔텍 주식
nouncing a rights offering, recorded a double-digit rebound, while ST PHARM and Boryung also rose following a report by PharmEdaily.
Stem Cell Plays Post Broad Gains
According to M주식매매프로그램
P Doctor, operated by KG Zeroin(formerly Market Point), companies classified as stem cell-related saw broad increases, with Nature Cell jumping 19.8 percent, Anterogen rising 6.6 percent, Corestem Che증권시주식동
mOn up 3.2 percent, and Tego Science edging up 0.2 percent.



Ra Jung-chan, chairman of Nature Cell, presents the company’s U.S. market strategy for its au능률교육 주식
tologous stem cell therapy for degenerative arthritis, JointStem, during a corporate briefing held in Yeouido at 11 a.m. on the 11th. (Photo by Kim Saemi)


Analysts att펀드가입방법
ribute the rally to optimism surrounding the government’s newly announced policy to boost advanced regenerative medicine. During a regulatory reform strategy meeting chaired by President Lee Jae-myung earlier in the day, the government said it would expand stem cell therapy coverage to chronic pain and musculoskeletal disorders and shorten the drug approval and review period to 240 days.
Nature Cell was the standout performer, surging 38.2 percent over the past three trading days following the policy announcement on the 16th. The rally is believed to stem from renewed expectations for JointStem, the company’s stem cell therapy for degenerative arthritis, which has been rejected three times by the Ministry of Food and Drug Safety. PharmEdaily previously reported on the challenges surrounding its approval prospects in the United States.
Nature Cell has shifted its focus to the U.S. market after domestic commercialization stalled. Chairman Ra Jung-chan said during a corporate presentation last month that the company aims to begin a Phase 3 clinical trial in the United States in the first half of next year.
T&R BIOFAB Rebounds on Profitability Hopes
T&R BIOFAB, a regenerative medicine company, closed at 2,095 won, up 16.0 percent from the previous session. It was the first double-digit gain in about four months, following six consecutive sessions of decline.
A company official said the share price rebound was likely driven by buying after excessive selling and renewed expectations for earnings growth led by its cosmetics subsidiary BlissPack, which performed strongly in the third quarter. T&R BIOFAB expects to break even in the fourth quarter and turn profitable next year.
BlissPack accounted for 62.8 percent of total revenue in the first half of the year, underscoring its contribution since being acquired. The parent company plans to pursue growth not only in cosmetics but also in its medical business.
T&R BIOFAB had planned a 40-billion-won rights offering allocated to shareholders, but the actual amount raised is expected to fall short. Of the initial plan, 22 billion won was to be used for debt repayment, 1.7 billion won for facilities, and 15.9 billion won for R&D.
The company said it has reached an agreement with some friendly investors to delay debt repayment. With around 7 billion won in cash equivalents and rising sales, it plans to allocate available capital to R&D and facility investment.



Yoon Won-soo, CEO of T&R BIOFAB (Photo by Lim Jeong-yeo)


ST PHARM and Boryung Bounce on Positive Coverage
ST PHARM and Boryung rebounded after PharmEdaily published a report that was made available to the public on the same day.
ST PHARM drew investor interest after it was reported that interim Phase 2a results for its next-generation HIV treatment would be presented at IDWeek 2025 in Atlanta on the 20th. The therapy, Firmitagravir (STP0404), inhibits viral replication through a different mechanism than existing HIV drugs, potentially blocking the replication cycle at its core.
A company official said oral presentation selection at IDWeek is significant, as even poster presentations face high competition. ST PHARM aims to pursue a license-out deal following the Phase 2a study. The global HIV treatment market is estimated at about 27 billion dollars.
Boryung also snapped a losing streak and climbed 2.4 percent after investor sentiment improved on coverage of its recent acquisition of global marketing rights for Sanofi’s cytotoxic anticancer drug Taxotere. PharmEdaily published an analysis of how the acquisition is expected to boost future earnings.
Taxotere reported global sales of 70 million euros (about 115.4 billion won) last year. With this deal, Boryung is expected to expand its oncology business from the domestic market to a global stage.
A company spokesperson said the acquisition marks the third oncology asset addition following Gemzar and Alimta and emphasized plans to strengthen long-term growth by directly producing and distributing original anticancer drugs in global markets.
나은경 (eeee@edaily.co.kr)